Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron Alyce Jacobson, Brian T Hill, John Timmerman, Houston Holmes, Ian W. Flinn, David Bernard Miklos, John M. Pagel, Marie José Kersten, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine Shen, Rubina Siddiqi, Ioana Kloos, Patrick Michael Reagan
Institutions: The University of Texas MD Anderson Cancer Center, Banner MD Anderson Cancer Center, Hackensack University Medical Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, Cleveland Clinic, University of California, Los Angeles, Texas Oncology, Sarah Cannon, Tennessee Oncology, Stanford Medicine, Stanford University, Amsterdam University Medical Centers, University of Amsterdam, Inserm, Centre Hospitalier Universitaire de Rennes, University of Miami, Kite (United States), University of Rochester Medicine
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281719458